Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102

-- Phase I Study of ONCOS-102 in Late-stage Refractory Cancer Patients Successfully Completed and Presented at CIMT Annual Meeting --Mainz, Germany 8th May 2014 - Oncos Therapeutics, Ltd., a clinical stage biotechnology company specializing in the development of targeted cancer immunotherapeutics, presented Phase 1 clinical data demonstrating that local administration of its lead compound, ONCOS-102, is able to induce a systemic, tumor-specific immune response in late-stage cancer patients. The data were presented in two separate podium presentations on May 7th and 8th at the Annual Meeting